MedTrace Logo

CADY Study ICORG 08-01

NCT00968682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2014-12-31

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer treated with trastuzumab may help doctors learn more about biomarkers related to heart dysfunction. It may also help doctors predict which patients will develop heart dysfunction.

PURPOSE: This clinical trial is studying biomarkers to see how well they predict heart dysfunction in women with breast cancer treated with trastuzumab.

Conditions

Interventions

BIOLOGICAL

trastuzumab

OTHER

laboratory biomarker analysis

PROCEDURE

assessment of therapy complications

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Principal Investigators

  • Ray McDermott, MD · Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-04-30

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968682 on ClinicalTrials.gov